Japan's Solasia begins Phase II trial of lymphoma drug darinaparsin
Japan-based Solasia Pharma has started an Asian Multinational Phase II trial of SP-02 (darinaparsin) for injection (SP-02L) to treat relapsed and refractory peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - March 28, 2016 Category: Pharmaceuticals Source Type: news
miRagen begins Phase I trial for MRG-106 to treat cutaneous T-cell lymphoma
US-based miRagen Therapeutics has started a Phase I trial of its anti-cancer product candidate MRG-106, a synthetic microRNA antagonist (LNA antimiR) of microRNA-155, to treat patients with lymphoma. (Source: Drug Development Technology)
Source: Drug Development Technology - March 3, 2016 Category: Pharmaceuticals Source Type: news
Lenalidomide trials show potential for expanding lymphoma, leukaemia indications
Positive findings from two clinical trials have been published for the immunomodulatory agent lenalidomide in patients with heavily pretreated mantle cell lymphoma, and in adults with T-cell leukaemia–lymphoma or peripheral T-cell lymphoma. (Source: MedWire News)
Source: MedWire News - February 21, 2016 Category: Consumer Health News Tags: Leukaemia Source Type: news
Primary CNS T-Cell Lymphoma of the Spinal CordPrimary CNS T-Cell Lymphoma of the Spinal Cord
The rare cause of this 82-year-old man's progressive lower back pain and lower extremity weakness was only confirmed after death. Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 19, 2015 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
Topical resiquimod effective for early-stage cutaneous T-cell lymphoma
Topical resiquimod was effective and well tolerated in patients with early-stage cutaneous T-cell lymphoma (CTCL), in some cases inducing regression in both treated and untreated lesions, according to researchers.
The mean number of prior unsuccessful therapies among the patients was 6, yet the... (Source: Skin and Allergy News)
Source: Skin and Allergy News - September 24, 2015 Category: Dermatology Source Type: news
Medical News Today: Topical drug leads to complete remission for some patients with rare skin lymphoma
Researchers reveal how a topical drug called resiquimod led to total remission for some patients with a cutaneous T cell lymphoma - a rare skin lymphoma. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - August 7, 2015 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Topical gel proves safe, effective treatment for patients with skin t cell lymphoma
Results of a phase one trial show that an investigational topical drug, resiquimod gel, causes regression of both treated and untreated tumor lesions and may completely remove cancerous cells from both sites in patients with early stage cutaneous T cell lymphoma (CTCL) – a rare type of non-Hodgkin lymphoma that affects the skin. Currently, there is no cure for CTCL aside from a bone marrow transplant. However, the new study shows that the topical gel can eliminate malignant T cells, leading to diminished lesions. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - August 6, 2015 Category: Science Source Type: news
Naloxone lotion improves disabling itch in CTCL
VANCOUVER, B.C. – Naloxone lotion appears to be a safe and effective treatment for the severe chronic itching that occurs in most patients with cutaneous T-cell lymphoma, Dr. Madeleine Duvic reported at the World Congress of Dermatology.
A major unmet need exists for better treatments for...googletag.display('div-gpt-ad-cta'); (Source: Skin and Allergy News)
Source: Skin and Allergy News - July 2, 2015 Category: Dermatology Source Type: news
Your NEJM Group Today: Cutaneous T-Cell Lymphoma, Sunscreen Use, Washington State IM Opportunity (FREE)
By the Editors
NEJM Group offers so many valuable resources for practicing clinicians. Here's what we chose for you today: … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - June 23, 2015 Category: Primary Care Source Type: news
Cutaneous T-Cell Lymphoma Therapeutic Development and Pipeline Market...
RnRMarketResearch.com adds “Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2015” to its store. The report provides an overview of the Cutaneous T-Cell Lymphoma’s therapeutic pipeline.(PRWeb April 07, 2015)Read the full story at http://www.prweb.com/releases/cutaneous-t-cell-lymphoma/pipeline-review-h1-2015/prweb12636381.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 7, 2015 Category: Pharmaceuticals Source Type: news
Takeda announces 4-year survival data from ADCETRIS® pivotal trial at ASH annual meeting
Takeda UK announced 4-year overall survival (OS) data from the ADCETRIS (brentuximab vedotin) pivotal Phase II clinical trial in relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). Brentuximab vedotin is an antibody-drug conjugate (ADC) directed to CD30, which is expressed in classical Hodgkin lymphoma (HL) and systemic ALCL, a type of T-cell lymphoma. (Source: Pharmacy Europe)
Source: Pharmacy Europe - December 10, 2014 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Clinical trials Practical therapeutics Industry News Other conferences & symposia Oncology Patient care ALCL antibody-drug conjugate brentuximab vedotin Hodgkin lymphoma Latest News Source Type: news
Autologous Stem Cell Transplant May Aid Some With Nodal PTCL
Prospective cohort study suggests benefit of ASCT for some with nodal peripheral T - cell lymphoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - November 11, 2014 Category: Cancer & Oncology Tags: Oncology, Pathology, Journal, Source Type: news
Agios begins Phase I/II trial of AG-221 to treat advanced solid tumours
Agios Pharmaceuticals has started a Phase I/II multicentre trial of AG-221 in patients with advanced solid tumours, including gliomas, as well as angioimmunoblastic T-cell lymphoma (AITL) that carry an isocitrate dehydrogenase-2 (IDH2) mutation. (Source: Drug Development Technology)
Source: Drug Development Technology - October 21, 2014 Category: Pharmaceuticals Source Type: news
Beleodaq (Belinostat) for the Treatment of Peripheral T-Cell Lymphoma (PTCL)
Beleodaq (belinostat) is a histone deacetylase (HDAC) inhibitor indicated for the treatment of relapsed or refractory (R/R) peripheral T-cell lymphoma (PTCL). (Source: Drug Development Technology)
Source: Drug Development Technology - September 10, 2014 Category: Pharmaceuticals Source Type: news
What is the Cause? Erythematous Rash
(MedPage Today) -- An elderly patient with known T-cell lymphoma and splenomegaly develops a well demarcated erythematous lesion on her upper arm. A biopsy of the lesion demonstrates a neutrophilic infiltrate. (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - August 5, 2014 Category: Dermatology Source Type: news
